Doing Well After a Year

Location:Home > About Us > Blogs >

Doing Well After a Year


Victoria Gray, who underwent a landmark treatment for sickle cell disease last year, has been at home in Forest, Miss., with her three kids, Jadasia Wash (left), Jamarius Wash (second from left) and Jaden Wash. Victoria Gray,NPR



Nearly a year on, Victoria Gray, who was the first person in the US to undergo a CRISPR-based treatment for sickle-cell disease, is doing well,NPR reports.


Vertex Pharmaceuticals and CRISPR Therapeutics launched a trial last year in which doctors remove cells from patients' bone marrow and edit them to produce fetal hemoglobin, before re-introducing the edited cells into the patients. Initial tests from last November suggested that Gray's cells were, as hoped, producing fetal hemoglobin and to a greater extent than researchers estimated would be needed to ease her disease symptoms.


According to NPR, the Sarah Cannon Research Institute's Haydar Frangoul and his colleagues gave an update on Gray's case and two beta-thalassemia cases at the European Hematology Association meeting earlier this month. It reports that 46 percent of Gray's hemoglobin is fetal hemoglobin, that fetal hemoglobin is present in 99.7 percent of her red blood cells, and that 81 percent of her bone marrow cells harbor the genetic alteration.


"To have it work in this way is extremely thrilling to see and extremely exciting," Frangoul tells NPR.



Ubigene Biosciences is co-founded by biological academics and elites from China, the United States, and France. We are located in Guangzhou Science City, which serves as a global center for high technology and innovation. Ubigene Biosciences has 1000㎡ office areas and laboratories, involving genome editing, cell biology technology, and zebrafish research. We provide products and services for plasmids, viruses, cells, and zebrafish. We aim to provide customers with better gene-editing tools for cell or animal research.

We developed CRISPR-U™ and CRISPR-B™(based on CRISPR/Cas9 technology) which is more efficient than general CRISPR/Cas9 in double-strand breaking, CRISPR-U™ and CRISPR-B™ can greatly improve the efficiency of homologous recombination, easily achieve knockout (KO), point mutation (PM) and knockin (KI) in vitro and in vivo. 

Genome Editing Platform
——Focusing on the Application of CRISPR-U™ and CRISPR-B™ Gene Editing Technology
1. Provides various types of gene-editing vectors for different species.
2. Provides different virus packaging services, including lentiviruses, adenoviruses and adeno-associated viruses.3. Provides high-quality services for gene knockout, point mutation and knockin cell lines

Cell Biology Platform
——Focusing on primary cell
1. Provides over 400 types of primary cells.
2. Provides culture strategies and related products for different cell types.3. Provides cell biology-related services such as cell isolation, extraction and validation.